FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 05/2025 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 05/2024”.

The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.

As of the end of May 2025 we identified the following current VC trends in Europe:

• Total Healthcare & Life Sciences funding reached EUR 5,149m (+26% vs. 2024)
• Biotech/Pharma received 36% of the total investment volume (EUR 1,886m) with metabolic disorders (including Diabetes, Obesity) being the leading indication (28%)
• In May, Azafaros (Netherlands) secured the highest transaction volume with EUR 132m, followed by GlycoEra (Switzerland) with EUR 115m and CellCentric (Great Britain) with EUR 106m
• GV (United States) is the most active investor (by deal volume in 2025), followed by Alphabet (United States) and Thrive Capital (United States)

To access the full report, please click here.